Age-related Macular Degeneration Market by Type, Treatment Modality, Delivery Method, Healthcare Setting, Distribution Channel - Global Forecast 2025-2030- Product Image

Sale

Age-related Macular Degeneration Market by Type, Treatment Modality, Delivery Method, Healthcare Setting, Distribution Channel - Global Forecast 2025-2030

Report
190 Pages
October 2024
Region: Global
360iResearch™
ID: 5665786

UP TO €681EUR$697USD£569GBP OFF until Dec 31^st 2024

The Age-related Macular Degeneration Market grew from USD 10.45 billion in 2023 to USD 11.10 billion in 2024. It is expected to continue growing at a CAGR of 6.67%, reaching USD 16.43 billion by 2030.

Age-related Macular Degeneration (AMD) is a significant health concern affecting the older population, leading to vision loss. The market scope encompasses the development, manufacturing, and distribution of diagnostic and therapeutic solutions. The necessity for AMD solutions increases with the aging population, emphasizing preventive and therapeutic care. Applications primarily involve pharmaceuticals - such as anti-VEGF agents - and diagnostic technologies including optical coherence tomography. End users are ophthalmology clinics, hospitals, and research institutions. Increasing prevalence due to the aging population, advancements in genetics, and technological improvements are key growth factors. Potential opportunities lie in personalized medicine and non-invasive treatments; however, companies face obstacles like high R&D costs and regulatory challenges. Transformative devices with AI integration for early diagnosis, gene therapy, and regenerative medicine are crucial innovation avenues. Despite the robust trajectory, with a trend toward non-invasive and home-based treatment and monitoring methodologies, limitations persist in addressing AMD forms unresponsive to current treatments and in rural accessibility to specialized care. Future research could focus on enhancing patient outcomes by developing more efficient drug delivery systems and exploring the genetic basis of AMD for targeted therapies. Companies should enhance collaborations with technological firms to create groundbreaking diagnostics tools, invest in genomic research, and navigate regulatory landscapes effectively to substantively seize emerging opportunities. An inward look at consumer education and support programs to emphasize early diagnosis and lifestyle adaptations would also fortify market positioning. Overall, the market is dynamic, driven by technological and medical advances, but demands strategic innovation, keen adaptation to regulatory environments, and sustained commitment to addressing unmet clinical needs for meaningful growth and impact.

Understanding Market Dynamics in the Age-related Macular Degeneration Market

The Age-related Macular Degeneration Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Growing number of geriatric population across the world
- Surging use of laser therapy and anti-angiogenesis drugs
- Increasing diagnostics facilities and technology for effective detection of AMD
Market Restraints
- Potential risk of drug recalls associated with AMD
Market Opportunities
- Significant government policies & funding for AMD
- Introduction of novel and advanced treatments based on cell therapy and tissue engineering
Market Challenges
- Stringent regulatory environment and complex approval of new treatments

Exploring Porter’s Five Forces for the Age-related Macular Degeneration Market

Porter’s Five Forces framework further strengthens the insights of the Age-related Macular Degeneration Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Age-related Macular Degeneration Market

External macro-environmental factors deeply influence the performance of the Age-related Macular Degeneration Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Age-related Macular Degeneration Market

The Age-related Macular Degeneration Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Age-related Macular Degeneration Market

The Age-related Macular Degeneration Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Age-related Macular Degeneration Market

The Age-related Macular Degeneration Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Age-related Macular Degeneration Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Inc., Alkeus Pharmaceuticals, Inc., Allegro Ophthalmics, LLC, Amgen Inc., Annexon, Inc., Apellis Pharmaceuticals, Inc., AsclepiX Therapeutics, Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Biocon Ltd, Biogen Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Formycon AG, Grifols, S.A., Ionis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Kodiak Sciences Inc., Lineage Cell Therapeutics, Inc., Lupin Limited, Merck & Co., Inc., Nicox S.A., Novartis AG, PanOptica, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sandoz Group AG, Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Age-related Macular Degeneration Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Dry Age-Related Macular Degeneration
- Wet Age-Related Macular Degeneration
Treatment Modality
- Pharmaceuticals
  - Anti-inflammatory Drugs
  - Anti-VEGF Agents
  - Antioxidants & Supplements
  - Gene Therapy Drugs
- Surgical Interventions
  - Laser Therapy
  - Macular Translocation Surgery
  - Photodynamic Therapy
  - Vitrectomy
Delivery Method
- Injectable
- Intravitreal implants
- Oral
Healthcare Setting
- Ambulatory Surgical Centers
- Hospitals
- Ophthalmology Clinics
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing number of geriatric population across the world
5.1.1.2. Surging use of laser therapy and anti-angiogenesis drugs
5.1.1.3. Increasing diagnostics facilities and technology for effective detection of AMD
5.1.2. Restraints
5.1.2.1. Potential risk of drug recalls associated with AMD
5.1.3. Opportunities
5.1.3.1. Significant government policies & funding for AMD
5.1.3.2. Introduction of novel and advanced treatments based on cell therapy and tissue engineering
5.1.4. Challenges
5.1.4.1. Stringent regulatory environment and complex approval of new treatments
5.2. Market Segmentation Analysis
5.2.1. Type: Targeting gradual vision loss in dry AMD and rapid impairment with tailored treatments
5.2.2. Treatment: Comprehensive management and innovative pharmaceutical treatments in age-related macular degeneration
5.2.3. Delivery Method: Innovative injectable methods for age-related macular degeneration
5.2.4. Healthcare Setting: Comprehensive care in AMD management through ASCs, hospitals, and clinics with advanced and cost-effective treatments
5.2.5. Distribution Channel: Proliferation of online pharmacies for distributing AMD drugs to ensure comprehensive patient care
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
5.5. Client Customization
5.5.1. Number of Patients Undergoing Treatments and Average Cost of Treatment By Country

6. Age-related Macular Degeneration Market, by Type

6.1. Introduction
6.2. Dry Age-Related Macular Degeneration
6.3. Wet Age-Related Macular Degeneration

7. Age-related Macular Degeneration Market, by Treatment Modality

7.1. Introduction
7.2. Pharmaceuticals
7.2.1. Anti-inflammatory Drugs
7.2.2. Anti-VEGF Agents
7.2.3. Antioxidants & Supplements
7.2.4. Gene Therapy Drugs
7.3. Surgical Interventions
7.3.1. Laser Therapy
7.3.2. Macular Translocation Surgery
7.3.3. Photodynamic Therapy
7.3.4. Vitrectomy

8. Age-related Macular Degeneration Market, by Delivery Method

8.1. Introduction
8.2. Injectable
8.3. Intravitreal implants
8.4. Oral

9. Age-related Macular Degeneration Market, by Healthcare Setting

9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals
9.4. Ophthalmology Clinics

10. Age-related Macular Degeneration Market, by Distribution Channel

10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies

11. Americas Age-related Macular Degeneration Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Age-related Macular Degeneration Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Age-related Macular Degeneration Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Genentech relaunches Susvimo for wet AMD with improved vision
14.3.2. Stealth BioTherapeutics launches phase 3 trial for elamipretide to combat dry age-related macular degeneration and improve patient outcomes
14.3.3. LambdaVision secures funding to advance preclinical trials of innovative artificial retina
14.3.4. Science Corporation acquires Pixium Vision's PRIMA retinal implant to enhance vision restoration for AMD patients
14.3.5. Researchers at HKUMed develop groundbreaking photoactivatable nanomedicine for safer and more effective age-related macular degeneration treatment
14.3.6. EyeBio secures USD 130 million Series A funding to advance Restoret therapy for age-related macular degeneration treatment
14.3.7. Astellas Pharma unveils treatment for age-related macular degeneration with promising efficacy and safety results
14.3.8. FDA provides clearance of clinical trials for Aviceda Therapeutics’ AVD-104 targeting age-related macular degeneration
14.3.9. Retinal Degeneration Fund’s major investment boosts biotech to advance age-related macular degeneration treatments and improve quality of life
14.4. Strategy Analysis & Recommendation
14.4.1. F. Hoffmann-La Roche Ltd.
14.4.2. Novartis AG
14.4.3. Bayer AG
14.4.4. Astellas Pharma Inc.

List of Figures

FIGURE 1. AGE-RELATED MACULAR DEGENERATION MARKET RESEARCH PROCESS
FIGURE 2. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2023 VS 2030 (%)
FIGURE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. AGE-RELATED MACULAR DEGENERATION MARKET DYNAMICS
TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTIOXIDANTS & SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY MACULAR TRANSLOCATION SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 59. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 60. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 61. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 62. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 63. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 66. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 69. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 70. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 96. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 97. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 98. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 99. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 100. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 103. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 104. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 105. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 106. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 107. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 111. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 112. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 113. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 114. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 117. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 118. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 119. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 120. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 121. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 125. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 126. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 127. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 128. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 131. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 132. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 133. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 134. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 135. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 138. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 139. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 140. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 141. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 142. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 145. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 146. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 147. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 148. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 149. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 152. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 153. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 154. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 155. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 156. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 158. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 159. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 160. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 161. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 162. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 163. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 166. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 167. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 168. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 169. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 170. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 179. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 181. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 182. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 183. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 184. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 185. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 188. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 189. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 190. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 191. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 192. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 194. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 195. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 197. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 198. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 199. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 201. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 202. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 203. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 204. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 205. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 206. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 208. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 209. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 210. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 211. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 212. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 213. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 218. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 219. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 220. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 222. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 223. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 224. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 225. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 226. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 227. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 243. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 244. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 245. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 246. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 247. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 248. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 250. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 251. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 252. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 253. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 254. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 255. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 257. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 258. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 259. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 260. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 261. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 262. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 285. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 286. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 287. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 288. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 289. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 290. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN AGE-RELATED MACULAR DEGENERATION

Companies Mentioned

The leading players in the Age-related Macular Degeneration market, which are profiled in this report, include:

AbbVie Inc.
Adverum Biotechnologies, Inc.
Alkeus Pharmaceuticals, Inc.
Allegro Ophthalmics, LLC
Amgen Inc.
Annexon, Inc.
Apellis Pharmaceuticals, Inc.
AsclepiX Therapeutics
Astellas Pharma Inc.
Bausch Health Companies Inc.
Bayer AG
Biocon Ltd
Biogen Inc.
Clearside Biomedical, Inc.
EyePoint Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Formycon AG
Grifols, S.A.
Ionis Pharmaceuticals, Inc.
Johnson & Johnson Services, Inc.
Kodiak Sciences Inc.
Lineage Cell Therapeutics, Inc.
Lupin Limited
Merck & Co., Inc.
Nicox S.A.
Novartis AG
PanOptica, Inc.
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Sandoz Group AG
Sun Pharmaceutical Industries, Ltd.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	190
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 11.1 Billion
Forecasted Market Value ( USD ) by 2030	$ 16.43 Billion
Compound Annual Growth Rate	6.6%
Regions Covered	Global
No. of Companies Mentioned	33

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3466EUR$3,545USD£2,895GBP €3851EUR$3,939USD£3,217GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6132EUR$6,272USD£5,122GBP €6813EUR$6,969USD£5,691GBP

Understanding Market Dynamics in the Age-related Macular Degeneration Market

Exploring Porter’s Five Forces for the Age-related Macular Degeneration Market

Applying PESTLE Analysis to the Age-related Macular Degeneration Market

Analyzing Market Share in the Age-related Macular Degeneration Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Age-related Macular Degeneration Market

Strategic Recommendations for Success in the Age-related Macular Degeneration Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Age-Related Macular Degeneration Market Size, Share and Trends Analysis Report by Product (Eylea, Lucentis), Disease (Wet AMD, Dry AMD), Distribution Channel, and Region 2024-2030

Age-Related Macular Degeneration Global Market Report 2024

Wet Age-Related Macular Degeneration (Wet AMD) - Market Insight, Epidemiology and Market Forecast - 2034

Macular Edema and Macular Degeneration Global Market Report 2024

Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

About the Age Related Macular Degeneration Market